Investigational RSV vaccine MV-012-968 (Dosage 2)

BIOLOGICAL2 trials

Sponsors

Meissa Vaccines, Inc.

Conditions

Respiratory Syncytial Virus (RSV)Respiratory Syncytial Virus Infections

Phase 1

Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children

CompletedNCT04444284

Meissa Vaccines, Inc.Respiratory Syncytial Virus Infections

Start: 2020-06-09End: 2021-05-07Updated: 2021-06-29

Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months

Meissa Vaccines, Inc.Respiratory Syncytial Virus (RSV)

Start: 2021-06-03End: 2023-10-31Target: 63Updated: 2022-08-02